Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes.

Xiao X, Tang A, Cox KS, Wen Z, Callahan C, Sullivan NL, Nahas DD, Cosmi S, Galli JD, Minnier M, Verma D, Babaoglu K, Su H, Bett AJ, Vora KA, Chen Z, Zhang L.

MAbs. 2019 Aug 23:1-13. doi: 10.1080/19420862.2019.1654304. [Epub ahead of print]

PMID:
31402751
2.

Immune response and reactogenicity of an unadjuvanted intradermally delivered human papillomavirus vaccine using a first generation Nanopatch™ in rhesus macaques: An exploratory, pre-clinical feasibility assessment.

Meyer BK, Kendall MAF, Williams DM, Bett AJ, Dubey S, Gentzel RC, Casimiro D, Forster A, Corbett H, Crichton M, Baker SB, Evans RK, Bhambhani A.

Vaccine X. 2019 Jun 20;2:100030. doi: 10.1016/j.jvacx.2019.100030. eCollection 2019 Aug 9.

3.

Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes.

Li L, Meng W, Horton M, DiStefano DR, Thoryk EA, Pfaff JM, Wang Q, Salazar GT, Barnes T, Doranz BJ, Bett AJ, Casimiro DR, Vora KA, An Z, Zhang N.

PLoS Pathog. 2019 Jun 6;15(6):e1007716. doi: 10.1371/journal.ppat.1007716. eCollection 2019 Jun.

4.

Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.

Awasthi S, Hook LM, Swaminathan G, Cairns TM, Brooks B, Smith JS, Ditto NT, Gindy ME, Bett AJ, Espeseth AS, Cohen GH, Friedman HM.

Vaccine. 2019 Jun 27;37(29):3770-3778. doi: 10.1016/j.vaccine.2019.05.068. Epub 2019 May 29.

5.

Efficiency Enhancement and Hysteresis Mitigation by Manipulation of Grain Growth Conditions in Hybrid Evaporated-Spin-coated Perovskite Solar Cells.

Rafizadeh S, Wienands K, Schulze PSC, Bett AJ, Andreani LC, Hermle M, Glunz S, Goldschmidt JC.

ACS Appl Mater Interfaces. 2019 Jan 9;11(1):722-729. doi: 10.1021/acsami.8b16963. Epub 2018 Dec 17.

PMID:
30511836
6.

Development and application of a higher throughput RSV plaque assay by immunofluorescent imaging.

Wen Z, Citron M, Bett AJ, Espeseth AS, Vora KA, Zhang L, DiStefano DJ.

J Virol Methods. 2019 Jan;263:88-95. doi: 10.1016/j.jviromet.2018.10.022. Epub 2018 Oct 28.

7.

Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.

Zhang L, Durr E, Galli JD, Cosmi S, Cejas PJ, Luo B, Touch S, Parmet P, Fridman A, Espeseth AS, Bett AJ.

Vaccine. 2018 Dec 18;36(52):8119-8130. doi: 10.1016/j.vaccine.2018.10.032. Epub 2018 Oct 16.

PMID:
30340881
8.

Detailed Investigation of Evaporated Perovskite Absorbers with High Crystal Quality on Different Substrates.

Cojocaru L, Wienands K, Kim TW, Uchida S, Bett AJ, Rafizadeh S, Goldschmidt JC, Glunz SW.

ACS Appl Mater Interfaces. 2018 Aug 8;10(31):26293-26302. doi: 10.1021/acsami.8b07999. Epub 2018 Jul 27.

PMID:
30016061
9.

Novel Low-Temperature Process for Perovskite Solar Cells with a Mesoporous TiO2 Scaffold.

Schulze PSC, Bett AJ, Winkler K, Hinsch A, Lee S, Mastroianni S, Mundt LE, Mundus M, Würfel U, Glunz SW, Hermle M, Goldschmidt JC.

ACS Appl Mater Interfaces. 2017 Sep 13;9(36):30567-30574. doi: 10.1021/acsami.7b05718. Epub 2017 Aug 29.

PMID:
28834429
10.

Co-Administration of Lipid Nanoparticles and Sub-Unit Vaccine Antigens Is Required for Increase in Antigen-Specific Immune Responses in Mice.

Thoryk EA, Swaminathan G, Meschino S, Cox KS, Gindy M, Casimiro DR, Bett AJ.

Vaccines (Basel). 2016 Dec 6;4(4). pii: E47.

11.

IMPre: An Accurate and Efficient Software for Prediction of T- and B-Cell Receptor Germline Genes and Alleles from Rearranged Repertoire Data.

Zhang W, Wang IM, Wang C, Lin L, Chai X, Wu J, Bett AJ, Dhanasekaran G, Casimiro DR, Liu X.

Front Immunol. 2016 Nov 4;7:457. eCollection 2016.

12.

Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.

Flynn JA, Durr E, Swoyer R, Cejas PJ, Horton MS, Galli JD, Cosmi SA, Espeseth AS, Bett AJ, Zhang L.

PLoS One. 2016 Oct 20;11(10):e0164789. doi: 10.1371/journal.pone.0164789. eCollection 2016.

13.

A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates.

Swaminathan G, Thoryk EA, Cox KS, Smith JS, Wolf JJ, Gindy ME, Casimiro DR, Bett AJ.

Sci Rep. 2016 Oct 5;6:34215. doi: 10.1038/srep34215.

14.

Wave optical simulation of the light trapping properties of black silicon surface textures.

Bett AJ, Eisenlohr J, Höhn O, Repo P, Savin H, Bläsi B, Goldschmidt JC.

Opt Express. 2016 Mar 21;24(6):A434-45. doi: 10.1364/OE.24.00A434.

PMID:
27136865
15.

A Rapid and Improved Method to Generate Recombinant Dengue Virus Vaccine Candidates.

Govindarajan D, Guan L, Meschino S, Fridman A, Bagchi A, Pak I, ter Meulen J, Casimiro DR, Bett AJ.

PLoS One. 2016 Mar 23;11(3):e0152209. doi: 10.1371/journal.pone.0152209. eCollection 2016.

16.

A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens.

Swaminathan G, Thoryk EA, Cox KS, Meschino S, Dubey SA, Vora KA, Celano R, Gindy M, Casimiro DR, Bett AJ.

Vaccine. 2016 Jan 2;34(1):110-9. doi: 10.1016/j.vaccine.2015.10.132. Epub 2015 Nov 10.

PMID:
26555351
17.

Preclinical and clinical development of a dengue recombinant subunit vaccine.

Manoff SB, George SL, Bett AJ, Yelmene ML, Dhanasekaran G, Eggemeyer L, Sausser ML, Dubey SA, Casimiro DR, Clements DE, Martyak T, Pai V, Parks DE, Coller BA.

Vaccine. 2015 Dec 10;33(50):7126-34. doi: 10.1016/j.vaccine.2015.09.101. Epub 2015 Oct 14. Review.

PMID:
26458804
18.

Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.

Govindarajan D, Meschino S, Guan L, Clements DE, ter Meulen JH, Casimiro DR, Coller BA, Bett AJ.

Vaccine. 2015 Aug 7;33(33):4105-16. doi: 10.1016/j.vaccine.2015.06.067. Epub 2015 Jul 3.

PMID:
26144900
19.

Efficient generation of monoclonal antibodies from single rhesus macaque antibody secreting cells.

Meng W, Li L, Xiong W, Fan X, Deng H, Bett AJ, Chen Z, Tang A, Cox KS, Joyce JG, Freed DC, Thoryk E, Fu TM, Casimiro DR, Zhang N, A Vora K, An Z.

MAbs. 2015;7(4):707-18. doi: 10.1080/19420862.2015.1051440.

20.

Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques.

DiStefano D, Antonello JM, Bett AJ, Medi MB, Casimiro DR, ter Meulen J.

Vaccine. 2013 Oct 1;31(42):4888-93. doi: 10.1016/j.vaccine.2013.07.034. Epub 2013 Aug 11.

PMID:
23941913
21.

A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge.

Reynolds MR, Weiler AM, Piaskowski SM, Piatak M Jr, Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, Lifson JD, Koff WC, Watkins DI.

Vaccine. 2012 Jun 22;30(30):4465-75. doi: 10.1016/j.vaccine.2012.04.082. Epub 2012 May 6.

22.

An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge.

Hutnick NA, Myles DJ, Hirao L, Scott VL, Ferraro B, Khan AS, Lewis MG, Miller CJ, Bett AJ, Casimiro D, Sardesai NY, Kim JJ, Shiver J, Weiner DB.

Vaccine. 2012 May 2;30(21):3202-8. doi: 10.1016/j.vaccine.2012.02.069. Epub 2012 Mar 8.

PMID:
22406458
23.

Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, DeSilva V, Fritts L, Bett AJ, Casimiro DR, Shiver JW, Robert-Guroff M, Robertson MN, McChesney MB, Gilbert PB, Miller CJ.

J Virol. 2012 Feb;86(4):2239-50. doi: 10.1128/JVI.06175-11. Epub 2011 Dec 7.

24.

Transcriptional profiling of vaccine-induced immune responses in humans and non-human primates.

Wang IM, Bett AJ, Cristescu R, Loboda A, ter Meulen J.

Microb Biotechnol. 2012 Mar;5(2):177-87. doi: 10.1111/j.1751-7915.2011.00317.x. Epub 2011 Nov 22. Review.

25.

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.

Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH.

Vaccine. 2011 Sep 23;29(42):7267-75. doi: 10.1016/j.vaccine.2011.07.021. Epub 2011 Jul 21. Review.

26.

Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.

Kandimalla ER, Struthers M, Bett AJ, Wisniewski T, Dubey SA, Jiang W, Precopio M, Sun Z, Wang H, Lan T, Agrawal S, Casimiro DR.

Cell Immunol. 2011;270(2):126-34. doi: 10.1016/j.cellimm.2011.03.027. Epub 2011 Apr 22.

PMID:
21570062
27.

Intratumor RNA interference of cell cycle genes slows down tumor progression.

Dharmapuri S, Peruzzi D, Marra E, Palombo F, Bett AJ, Bartz SR, Yong M, Ciliberto G, La Monica N, Buser CA, Toniatti C, Aurisicchio L.

Gene Ther. 2011 Jul;18(7):727-33. doi: 10.1038/gt.2011.27. Epub 2011 Mar 10.

PMID:
21390070
28.

Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.

Bett AJ, Dubey SA, Mehrotra DV, Guan L, Long R, Anderson K, Collins K, Gaunt C, Fernandez R, Cole S, Meschino S, Tang A, Sun X, Gurunathan S, Tartaglia J, Robertson MN, Shiver JW, Casimiro DR.

Vaccine. 2010 Nov 23;28(50):7881-9. doi: 10.1016/j.vaccine.2010.09.079. Epub 2010 Oct 23.

PMID:
20937317
29.

Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques.

Hirao LA, Wu L, Satishchandran A, Khan AS, Draghia-Akli R, Finnefrock AC, Bett AJ, Betts MR, Casimiro DR, Sardesai NY, Kim JJ, Shiver JW, Weiner DB.

Mol Ther. 2010 Aug;18(8):1568-76. doi: 10.1038/mt.2010.112. Epub 2010 Jun 15.

30.

Synthesis and immunological activities of novel agonists of toll-like receptor 9.

Struthers M, Bett AJ, Wisniewski T, Dubey SA, Precopio M, Jiang W, Sun Z, Wang H, Nowak I, Putta MR, Yu D, Tang JX, Kandimalla ER, Agrawal S, Casimiro DR.

Cell Immunol. 2010;263(1):105-13. doi: 10.1016/j.cellimm.2010.03.005. Epub 2010 Mar 10.

PMID:
20381019
31.

Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.

Aste-Amézaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, Huang L, Vitelli S, Vo KT, Haytko P, Zhao JZ, Baleydier F, L'Heureux S, Wang H, Gordon WR, Thoryk E, Andrawes MB, Tiyanont K, Stegmaier K, Roti G, Ross KN, Franlin LL, Wang H, Wang F, Chastain M, Bett AJ, Audoly LP, Aster JC, Blacklow SC, Huber HE.

PLoS One. 2010 Feb 8;5(2):e9094. doi: 10.1371/journal.pone.0009094.

32.

Robust, vaccine-induced CD8(+) T lymphocyte response against an out-of-frame epitope.

Maness NJ, Wilson NA, Reed JS, Piaskowski SM, Sacha JB, Walsh AD, Thoryk E, Heidecker GJ, Citron MP, Liang X, Bett AJ, Casimiro DR, Watkins DI.

J Immunol. 2010 Jan 1;184(1):67-72. doi: 10.4049/jimmunol.0903118. Epub 2009 Nov 30.

33.

Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.

Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, Bett AJ, Casimiro DR, Shiver JW, DiNubile MJ, Quirk E; Merck V526-001 Study Group.

Clin Vaccine Immunol. 2009 Sep;16(9):1285-92. doi: 10.1128/CVI.00144-09. Epub 2009 Jul 15.

34.

Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge.

Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, Bett AJ, Liang X, Wang F, Thoryk E, Heidecker GJ, Citron MP, Huang L, Lin J, Vitelli S, Ahn CD, Kaizu M, Maness NJ, Reynolds MR, Friedrich TC, Loffredo JT, Rakasz EG, Erickson S, Allison DB, Piatak M Jr, Lifson JD, Shiver JW, Casimiro DR, Shaw GM, Hahn BH, Watkins DI.

J Virol. 2009 Jul;83(13):6508-21. doi: 10.1128/JVI.00272-09. Epub 2009 Apr 29.

35.

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag.

Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, Tobery TW, Davies ME, McDermott AB, O'Connor DH, Fridman A, Bagchi A, Tussey LG, Bett AJ, Finnefrock AC, Fu TM, Tang A, Wilson KA, Chen M, Perry HC, Heidecker GJ, Freed DC, Carella A, Punt KS, Sykes KJ, Huang L, Ausensi VI, Bachinsky M, Sadasivan-Nair U, Watkins DI, Emini EA, Shiver JW.

J Virol. 2005 Dec;79(24):15547-55.

36.

Serotype specificity of adenovirus purification using anion-exchange chromatography.

Konz JO, Livingood RC, Bett AJ, Goerke AR, Laska ME, Sagar SL.

Hum Gene Ther. 2005 Nov;16(11):1346-53.

PMID:
16259569
37.

Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.

Casimiro DR, Bett AJ, Fu TM, Davies ME, Tang A, Wilson KA, Chen M, Long R, McKelvey T, Chastain M, Gurunathan S, Tartaglia J, Emini EA, Shiver J.

J Virol. 2004 Oct;78(20):11434-8.

38.

Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines.

Aste-Amézaga M, Bett AJ, Wang F, Casimiro DR, Antonello JM, Patel DK, Dell EC, Franlin LL, Dougherty NM, Bennett PS, Perry HC, Davies ME, Shiver JW, Keller PM, Yeager MD.

Hum Gene Ther. 2004 Mar;15(3):293-304.

PMID:
15018738
39.

T-cell response to adenovirus hexon and DNA-binding protein in mice.

McKelvey T, Tang A, Bett AJ, Casimiro DR, Chastain M.

Gene Ther. 2004 May;11(9):791-6.

PMID:
14961070
40.

Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses.

Youil R, Toner TJ, Su Q, Casimiro D, Shiver JW, Chen L, Bett AJ, Rogers BM, Burden EC, Tang A, Chen M, Emini EA, Kaslow DC, Aunins JG, Altaras NE.

Hum Gene Ther. 2003 Jul 1;14(10):1017-34.

PMID:
12869219
41.

Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW.

J Virol. 2003 Jun;77(11):6305-13.

42.

PYK2 autophosphorylation, but not kinase activity, is necessary for adhesion-induced association with c-Src, osteoclast spreading, and bone resorption.

Lakkakorpi PT, Bett AJ, Lipfert L, Rodan GA, Duong LT.

J Biol Chem. 2003 Mar 28;278(13):11502-12. Epub 2003 Jan 3.

43.

Hexon gene switch strategy for the generation of chimeric recombinant adenovirus.

Youil R, Toner TJ, Su Q, Chen M, Tang A, Bett AJ, Casimiro D.

Hum Gene Ther. 2002 Jan 20;13(2):311-20.

PMID:
11812286
44.

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA.

Nature. 2002 Jan 17;415(6869):331-5.

PMID:
11797011
45.

Inhibition of osteoclast function by adenovirus expressing antisense protein-tyrosine kinase 2.

Duong LT, Nakamura I, Lakkakorpi PT, Lipfert L, Bett AJ, Rodan GA.

J Biol Chem. 2001 Mar 9;276(10):7484-92. Epub 2000 Dec 1.

46.

Optimization of the helper-dependent adenovirus system for production and potency in vivo.

Sandig V, Youil R, Bett AJ, Franlin LL, Oshima M, Maione D, Wang F, Metzker ML, Savino R, Caskey CT.

Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1002-7.

47.

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate.

Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8795-800.

48.

An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene.

Morsy MA, Gu M, Motzel S, Zhao J, Lin J, Su Q, Allen H, Franlin L, Parks RJ, Graham FL, Kochanek S, Bett AJ, Caskey CT.

Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7866-71.

49.
50.

DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309.

Bett AJ, Krougliak V, Graham FL.

Virus Res. 1995 Nov;39(1):75-82.

PMID:
8607286

Supplemental Content

Support Center